ZURA BIO LIMITED Increase (Decrease) in Accrued Liabilities
ZURA BIO LIMITED (ZURA) reported Increase (Decrease) in Accrued Liabilities of $912.05 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2023-03-28
- ZURA BIO LIMITED increase (decrease) in accrued liabilities for the quarter ending 2022-12-31 was $275.45K.
- ZURA BIO LIMITED increase (decrease) in accrued liabilities for the quarter ending 2022-09-30 was $107.22K.
- ZURA BIO LIMITED increase (decrease) in accrued liabilities for the quarter ending 2022-06-30 was $553.80K.
- ZURA BIO LIMITED increase (decrease) in accrued liabilities for the quarter ending 2022-03-31 was -$24.42K.
- ZURA BIO LIMITED increase (decrease) in accrued liabilities for fiscal 2022 was $912.05K.
| Period end | Increase (Decrease) in Accrued Liabilities 1 month | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 4 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 7 month | Increase (Decrease) in Accrued Liabilities 7 month as first filed | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 10 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $275.45K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $382.67K derived: sum of 2 quarters · filed 2023-03-28 | $936.47K derived: sum of 3 quarters · filed 2023-03-28 | $912.05K 10-K · filed 2023-03-28 | |||||
| 2022-09-30 | $107.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $661.02K derived: sum of 2 quarters · filed 2022-11-14 | $636.60K 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | $553.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $529.38K 10-Q · filed 2022-08-12 | |||||||
| 2022-03-31 | -$24.42K 10-Q · filed 2022-05-13 | ||||||||
| 2021-12-31 | $114.56K 10-K · filed 2023-03-28 | ||||||||
| 2021-09-30 | $18.28K 10-Q · filed 2022-11-14 | $18.28K 10-Q · filed 2021-11-19 | |||||||
| 2021-06-30 | $2.95K 10-Q · filed 2022-08-12 | ||||||||
| 2021-03-31 | $4.92K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |